HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
Trial details
- Registry ID
- NCT05127226
- Phase
- Phase 1, Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman SyndromeNCT05127226 | IONS | Phase 1, Phase 2 | Active not recruiting | 2032-03Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |